• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估格鲁吉亚儿童特应性皮炎的严重程度:炎症血液标志物与湿疹面积及严重程度指数的相关性

Assessing Atopic Dermatitis severity in children from Georgia: the correlation of inflammatory blood markers to the Eczema Area and Severity Index.

作者信息

Karawita Janadi, Kabachi Faiza Yasmine, Modak Aliya, Venkiteswaran Arun, Haseeb Rawiah, Papiashvili Nikoloz, Jacob Kevin, Abralava Veriko

机构信息

Faculty of Medicine, Tbilisi State Medical University, Tbilisi, Georgia.

出版信息

Expert Rev Clin Immunol. 2025 Sep;21(9):1287-1295. doi: 10.1080/1744666X.2025.2549826. Epub 2025 Aug 25.

DOI:10.1080/1744666X.2025.2549826
PMID:40823698
Abstract

BACKGROUND

Atopic dermatitis (AD) is a chronic inflammatory skin condition prevalent among children worldwide. Systemic inflammation is a key factor in its pathophysiology. Correlating blood markers with Eczema Area and Severity Index (EASI) can reveal information about the severity and activity of the disorder, allowing for more focused treatment.

METHODS

A retrospective analysis was conducted on 22 patients aged 3 months to 18  years. Blood parameters, such as Eosinophil Relative Count (ERC), Neutrophil/Lymphocyte Ratio (NLR), Eosinophil/Lymphocyte Ratio (ELR), and Basophil/Lymphocyte Ratio (BLR), were correlated with the Eczema Area and Severity Index (EASI).

RESULTS

A strong positive correlation was observed between EASI scores and ERC ( = 0.69,  < 0.001) and with ELR ( = 0.71,  < 0.001). No statistical significance was seen between EASI scores and the NLR ( = 0.2059,  = 0.3578) and BLR ( = 0.1026,  = 0.6494). No significant association was found between age and EASI scores ( =  -0.0351,  = 0.8767).

CONCLUSIONS

ERC and ELR have the potential to serve as objective blood markers for assessing AD severity. However, more research in pediatric populations with a larger sample size is needed to establish a conclusive association for clinical practice.

摘要

背景

特应性皮炎(AD)是一种在全球儿童中普遍存在的慢性炎症性皮肤病。全身炎症是其病理生理学的关键因素。将血液标志物与湿疹面积和严重程度指数(EASI)相关联,可以揭示有关该疾病严重程度和活动情况的信息,从而实现更有针对性的治疗。

方法

对22例年龄在3个月至18岁之间的患者进行了回顾性分析。将血液参数,如嗜酸性粒细胞相对计数(ERC)、中性粒细胞/淋巴细胞比值(NLR)、嗜酸性粒细胞/淋巴细胞比值(ELR)和嗜碱性粒细胞/淋巴细胞比值(BLR),与湿疹面积和严重程度指数(EASI)进行关联分析。

结果

观察到EASI评分与ERC(=0.69,<0.001)和ELR(=0.71,<0.001)之间存在强正相关。EASI评分与NLR(=0.2059,=0.3578)和BLR(=0.1026,=0.6494)之间无统计学意义。年龄与EASI评分之间未发现显著关联(= -0.0351,=0.8767)。

结论

ERC和ELR有可能作为评估AD严重程度的客观血液标志物。然而,需要对更大样本量的儿科人群进行更多研究,以建立用于临床实践的确定性关联。

相似文献

1
Assessing Atopic Dermatitis severity in children from Georgia: the correlation of inflammatory blood markers to the Eczema Area and Severity Index.评估格鲁吉亚儿童特应性皮炎的严重程度:炎症血液标志物与湿疹面积及严重程度指数的相关性
Expert Rev Clin Immunol. 2025 Sep;21(9):1287-1295. doi: 10.1080/1744666X.2025.2549826. Epub 2025 Aug 25.
2
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years.使用曲罗芦单抗治疗长达4年的头颈部特应性皮炎患者的长期疾病控制和最小疾病活动度
Am J Clin Dermatol. 2025 Mar 14. doi: 10.1007/s40257-025-00931-1.
3
Vesicoureteral Reflux膀胱输尿管反流
4
Abrocitinib, tralokinumab and upadacitinib for treating moderate-to-severe atopic dermatitis.阿布昔替尼、特利鲁单抗和乌帕替尼治疗中重度特应性皮炎。
Health Technol Assess. 2024 Jan;28(4):1-113. doi: 10.3310/LEXB9006.
5
Educational and psychological interventions for managing atopic dermatitis (eczema).管理特应性皮炎(湿疹)的教育和心理干预措施。
Cochrane Database Syst Rev. 2024 Aug 12;8(8):CD014932. doi: 10.1002/14651858.CD014932.pub2.
6
Topical tacrolimus for atopic dermatitis.外用他克莫司治疗特应性皮炎。
Cochrane Database Syst Rev. 2015 Jul 1;2015(7):CD009864. doi: 10.1002/14651858.CD009864.pub2.
7
Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial.瑞扎布替尼治疗中重度特应性皮炎患者的疗效和安全性:一项概念验证性II期临床试验的16周结果
Br J Dermatol. 2025 Aug 18;193(3):424-433. doi: 10.1093/bjd/ljaf156.
8
Harmonizing measurement of eczema control: mapping scores between the Atopic Dermatitis Control Tool and the Recap of Atopic Eczema instrument.协调湿疹控制的测量:绘制特应性皮炎控制工具和特应性湿疹总结工具之间的评分对应关系。
Br J Dermatol. 2025 Aug 18;193(3):451-457. doi: 10.1093/bjd/ljaf167.
9
Clinical Characteristics of Super Responders to Anti-IL-4Rα Biologic Therapy in Atopic Dermatitis.特应性皮炎中抗IL-4Rα生物疗法超级应答者的临床特征
Dermatol Ther (Heidelb). 2025 Aug 16. doi: 10.1007/s13555-025-01514-y.
10
Specific allergen immunotherapy for the treatment of atopic eczema.特异性变应原免疫疗法治疗特应性皮炎
Cochrane Database Syst Rev. 2016 Feb 12;2(2):CD008774. doi: 10.1002/14651858.CD008774.pub2.